TARGT Lung Liquid (Basic) gene panel focuses specifically on lung cancer, offering a comprehensive evaluation of common driver mutations associated with the disease.

The gene panel includes genomic markers that NCCN and the FDA approve as actionable targets in lung cancer. By detecting these approved alterations, this panel enables oncologists to make informed treatment decisions based on established guidelines and approved therapies, enhancing the likelihood of positive treatment outcomes.

The gene panel utilizes liquid biopsy, specifically circulating tumor DNA (ctDNA) analysis, for genomic profiling.

The gene panel provides oncologists with clinically actionable insights from patients’ peripheral blood. The detailed genetic information obtained through this gene panel testing allows oncologists to make informed treatment decisions.

Our Cancer Gene Panel thoroughly assesses clinically relevant genes, ensuring accurate and reliable results.

We utilize cutting-edge next generation sequencing technology to deliver precise and detailed genetic information.

Our team of experienced genetic counselors and healthcare professionals will guide you through the testing process, answer your questions, and help you understand the implications of the results.

We adhere to strict privacy protocols and maintain the confidentiality of your genetic information.